Skip to content

Mooy Pharma: what changed

BE 0846.742.494NACE 47.730, Retail sale of pharmaceutical productsOther company

Position among the sector peers

What moved between 2024 and 2025

Net result for the year
€145,608
2024 · -€27,227+€172,834
Equity
€365,338
2024 · €221,396+€143,942
Cash
€183,984
2024 · €145,279+€38,705
Balance sheet total
€1.7m
2024 · €1.7m+€11,997

Largest movements

2024 to 2025
Assets
  • Receivables within one year -€64,939

    down €64,939 (-16.7%), from €388,485 to €323,546

    of which Trade receivables: -€207,407

  • Stocks and contracts +€49,560

    up €49,560 (+25.6%), from €193,381 to €242,941

  • Cash +€38,705

    up €38,705 (+26.6%), from €145,279 to €183,984

    mainly Net result for the year (+€145,608) and Debts after one year (+€107,941)

Equity and liabilities
  • Trade debts -€228,176

    down €228,176 (-69.9%), from €326,504 to €98,328

  • Reserves +€143,942

    up €143,942 (+68.9%), from €208,996 to €352,938

  • Debts after one year +€107,941

    up €107,941 (+13.9%), from €774,912 to €882,853

  • Other debts -€40,163

    down €40,163 (-13.5%), from €297,285 to €257,122

  • Tax, wage and social debts +€29,701

    up €29,701 (+224%), from €13,233 to €42,935

    of which Taxes: +€28,850

Income statement
  • Other operating charges -€102,798

    down €102,798 (-88.9%), from €115,601 to €12,803

  • Gross operating margin +€79,378

    up €79,378 (+32.5%), from €244,457 to €323,835

  • Taxes +€39,692

    up €39,692 (+13,273%), from €299 to €39,991

  • Staff costs -€24,924

    down €24,924 (-38.2%), from €65,285 to €40,360

  • Financial income +€6,978

    up €6,978 (+465%), from €1,501 to €8,479

Change in the result, 2024 to 2025

effect on the result

For each income-statement line you see the change as its effect on the result.

Result 2024 -€27,227
Gross operating margin +€79,378
Staff costs +€24,924
Depreciation +€1,118
Other operating charges +€102,798
Other operating items -€142
Financial income +€6,978
Financial charges -€2,527
Taxes -€39,692
Result 2025 €145,608
raises the resultlowers the resultnot broken down further in the accounts

Derived cash bridge

cash 2024 to 2025

The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.

From operations -€14,735
Investment -€54,699
Financing +€108,138
Cash 2024 €145,279
Net result for the year +€145,608
Depreciation +€67,342
Stocks and contracts -€49,560
Receivables within one year +€64,939
Deferred charges and accrued income -€1,314
Trade debts -€228,176
Tax, wage and social debts +€29,701
Other debts -€40,163
Accrued charges and deferred income -€3,111
Investment in fixed assets (net) -€54,699
Debts after one year +€107,941
Current portion of long-term debt +€1,863
Contributions, distributions and other -€1,666
Cash 2025 €183,984
brings cash intakes cash out
Every line side by side 49 lines
Line Code 2024 2025 Change %
Total assets 20/58 €1,726,551 €1,738,548 +€11,997 +0.7%
Fixed assets 21/28 €996,495 €983,852 -€12,643 -1.3%
Tangible fixed assets 22/27 €993,995 €981,352 -€12,643 -1.3%
Land and buildings 22 €214,130 €205,417 -€8,713 -4.1%
Plant, machinery and equipment 23 €101,216 €92,638 -€8,577 -8.5%
Furniture and vehicles 24 €477 €845 +€368 +77.0%
Other tangible fixed assets 26 €678,172 €682,451 +€4,279 +0.6%
Financial fixed assets 28 €2,500 €2,500 = 0.0%
Current assets 29/58 €730,056 €754,696 +€24,640 +3.4%
Stocks and contracts in progress 3 €193,381 €242,941 +€49,560 +25.6%
Stocks 30/36 €193,381 €242,941 +€49,560 +25.6%
Amounts receivable within one year 40/41 €388,485 €323,546 -€64,939 -16.7%
Trade receivables 40 €343,165 €135,757 -€207,407 -60.4%
Other amounts receivable 41 €45,320 €187,789 +€142,468 +314%
Cash at bank and in hand 54/58 €145,279 €183,984 +€38,705 +26.6%
Deferred charges and accrued income 490/1 €2,911 €4,225 +€1,314 +45.1%
Total equity and liabilities 10/49 €1,726,551 €1,738,548 +€11,997 +0.7%
Equity 10/15 €221,396 €365,338 +€143,942 +65.0%
Contributions 10/11 €12,400 €12,400 = 0.0%
Reserves 13 €208,996 €352,938 +€143,942 +68.9%
Distributable reserves 133 €208,996 €352,938 +€143,942 +68.9%
Profit (loss) carried forward 14 €0 €0 =
Amounts payable 17/49 €1,505,155 €1,373,211 -€131,944 -8.8%
Amounts payable after more than one year 17 €774,912 €882,853 +€107,941 +13.9%
Financial debts 170/4 €774,912 €882,853 +€107,941 +13.9%
Amounts payable within one year 42/48 €723,437 €486,663 -€236,774 -32.7%
Current portion of amounts payable after more than one year 42 €86,414 €88,277 +€1,863 +2.2%
Trade debts 44 €326,504 €98,328 -€228,176 -69.9%
Suppliers 440/4 €326,504 €98,328 -€228,176 -69.9%
Taxes, remuneration and social security 45 €13,233 €42,935 +€29,701 +224%
Taxes 450/3 €2,797 €31,647 +€28,850 +1,032%
Remuneration and social security 454/9 €10,437 €11,288 +€851 +8.2%
Other amounts payable 47/48 €297,285 €257,122 -€40,163 -13.5%
Accrued charges and deferred income 492/3 €6,806 €3,695 -€3,111 -45.7%
Remuneration, social security and pensions 62 €65,285 €40,360 -€24,924 -38.2%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets 630 €68,460 €67,342 -€1,118 -1.6%
Write-downs on stocks, contracts in progress and trade receivables: additions (reversals) 631/4 €0 - =
Other operating charges 640/8 €115,601 €12,803 -€102,798 -88.9%
Non-recurring operating charges 66A €63 €205 +€142 +226%
Gross operating margin 9900 €244,457 €323,835 +€79,378 +32.5%
Operating profit (loss) 9901 -€4,952 €203,124 +€208,076
Financial income 75/76B €1,501 €8,479 +€6,978 +465%
Recurring financial income 75 €1,501 €8,479 +€6,978 +465%
Financial charges 65/66B €23,477 €26,004 +€2,527 +10.8%
Recurring financial charges 65 €23,477 €26,004 +€2,527 +10.8%
Profit (loss) for the period before taxes 9903 -€26,928 €185,599 +€212,527
Income taxes 67/77 €299 €39,991 +€39,692 +13,273%
Profit (loss) for the period 9904 -€27,227 €145,608 +€172,834
Profit (loss) for the period to be appropriated 9905 -€27,227 €145,608 +€172,834

Value

latest balance sheet 31-12-2025 · indication, not a valuation or advice

Value of the equity

Indication, not a valuation or advice
€451,569 to €559,129

Midpoint €496,385 · 50% capitalised earnings, 50% adjusted equity

Capitalisation rate 12% result over 3 years, excluding non-recurring income and charges earnings weight 50%

Worked out with Checked's starting values, not your estimate. Change the assumptions and the value follows.

Adjusted equity €365,338
Capitalised earnings €537,800 to €752,920
Indication €451,569 to €559,129

Adjusted equity

balance sheet 31-12-2025
Equity (10/15)
€365,338
Revaluation of assets
€0
Deferred tax on the revaluation
€0
Other adjustment
€0
Adjusted equity
€365,338

Capitalised earnings

net result for the year (9904)
2025
€145,608
excluding non-recurring income and charges
€145,813
2024
-€27,227
excluding non-recurring income and charges
-€27,164
2023
€107,227
2022
€61,098
excluding non-recurring income and charges
€61,250
2021
€34,560
excluding non-recurring income and charges
€34,613
Average result, excluding non-recurring income and charges
€75,292
Divided by the capitalisation rate
14% / 12% / 10%
Capitalised earnings
€537,800 / €627,433 / €752,920

Limits of the indication

  • Checked holds no market prices or comparable transactions.
  • Anything after the latest accounts and items off the balance sheet (guarantees, leases, disputes) are left out.
  • Checked does not know the real value of buildings, stock and receivables. Enter your own revaluation or adjustment for it.
  • The result is not corrected for the manager's pay. If the company pays less or more than a market salary, the capitalised earnings are too high or too low.
  • The owner's role in the business, synergies for a buyer and the tax consequences of a sale are left out.

For a valuation to base a decision on, go to a company auditor or a certified accountant.

Calculation and sources

Source: filed annual accounts (NBB) and main activity (KBO). The movements compare the financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. The value is an indication, not a valuation or advice. Prepared on 21 November 2026 via checked.be.